Earnings ·
PTC Therapeutics reports Q3 revenue of $358 million, raises full-year guidance to $1.29-$1.32 billion
PTCTPtc Therapeutics, Inc.
PTC Therapeutics reported third-quarter total revenue of $358 million, driven by a 106% increase in product sales to $276 million led by Sephience. The company raised its full-year 2026 total revenue guidance to $1.29-$1.32 billion and product revenue guidance to $960-$990 million. PTC also acquired the ST-920 Fabry disease gene therapy for an $111 million upfront payment, with a BLA submission expected in Q4 2026. The company reported a net loss of $51.7 million due to acquisition costs and interest expenses, while maintaining cash reserves of $2.1 billion. PTC Therapeutics is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders.